Bristol-Myers Squibb (NYSE:BMY) Shares Purchased by Trust Point Inc.

Trust Point Inc. raised its holdings in Bristol-Myers Squibb (NYSE:BMYFree Report) by 1.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,423 shares of the biopharmaceutical company’s stock after purchasing an additional 172 shares during the period. Trust Point Inc.’s holdings in Bristol-Myers Squibb were worth $533,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in BMY. Childress Capital Advisors LLC increased its stake in shares of Bristol-Myers Squibb by 17.6% in the fourth quarter. Childress Capital Advisors LLC now owns 7,018 shares of the biopharmaceutical company’s stock worth $397,000 after buying an additional 1,051 shares during the last quarter. F&V Capital Management LLC increased its position in shares of Bristol-Myers Squibb by 0.9% in the 4th quarter. F&V Capital Management LLC now owns 172,158 shares of the biopharmaceutical company’s stock worth $9,737,000 after purchasing an additional 1,600 shares during the last quarter. GEN Financial Management INC. bought a new position in shares of Bristol-Myers Squibb during the fourth quarter worth about $222,000. Fourpath Capital Management LLC grew its stake in Bristol-Myers Squibb by 1.9% in the fourth quarter. Fourpath Capital Management LLC now owns 24,549 shares of the biopharmaceutical company’s stock worth $1,388,000 after purchasing an additional 466 shares in the last quarter. Finally, Optas LLC bought a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $259,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Stock Performance

BMY opened at $59.15 on Wednesday. The business has a 50 day moving average price of $57.63 and a two-hundred day moving average price of $53.47. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. The company has a market capitalization of $119.97 billion, a price-to-earnings ratio of -16.48, a price-to-earnings-growth ratio of 2.10 and a beta of 0.45. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $61.10.

Bristol-Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were paid a dividend of $0.62 per share. The ex-dividend date was Friday, January 3rd. This represents a $2.48 annualized dividend and a yield of 4.19%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -69.08%.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Wolfe Research initiated coverage on Bristol-Myers Squibb in a research report on Friday, November 15th. They issued a “peer perform” rating for the company. Leerink Partners raised shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $55.00 to $73.00 in a report on Tuesday, November 12th. Daiwa Capital Markets raised shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. Bank of America reaffirmed a “neutral” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Finally, Sanford C. Bernstein started coverage on shares of Bristol-Myers Squibb in a report on Thursday, October 17th. They issued a “market perform” rating and a $56.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $56.93.

View Our Latest Stock Report on Bristol-Myers Squibb

Bristol-Myers Squibb Profile

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Recommended Stories

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYFree Report).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.